CD7 CAR T cells that have been genetically modified to prevent surface CD7 expression have demonstrated high rates of remission in patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (10, 11). Here, CD7 is linked to acute lymphoblastic leukemia.